Opioid-induced constipation and narcotic bowel syndrome

Prevent opioid constipation from the start with a stimulant laxative, reserve peripheral opioid antagonists for established constipation without obstruction, and suspect narcotic bowel syndrome when abdominal pain worsens as opioid doses rise.

1. Constipation is the commonest opioid side effect. In cancer pain, constipation and nausea and vomiting are the most common adverse effects; about 1 to 2 in 10 people stop opioids because of intolerable adverse effects ¹.
2. Prevent it actively. CDC advises hydration, fiber and activity, and prophylactic therapy such as senna, with or without a stool softener, if opioids are used for more than a few days; avoid softeners or fiber alone ².
3. Methylnaltrexone treats established constipation. This peripherally acting opioid antagonist is indicated for opioid-induced constipation in chronic noncancer pain and in advanced illness ³.
4. Rule out obstruction first. Methylnaltrexone is contraindicated in known or suspected mechanical GI obstruction; watch for perforation, severe diarrhea and opioid withdrawal, especially when the blood-brain barrier is disrupted ³.
5. Narcotic bowel syndrome is paradoxical pain. Abdominal pain persists or worsens despite continued or escalating opioids, affecting an estimated 4.2–6.4% of chronic opioid users ⁴.
6. Its mechanism is central, not motility. Unlike opioid-induced bowel dysfunction, narcotic bowel syndrome probably reflects glial activation and descending facilitation; supervised opioid withdrawal with a strong therapeutic relationship is the treatment ⁴⁵.

Severe, persistent or worsening abdominal pain on methylnaltrexone can signal gastrointestinal perforation; stop the drug, and weigh risk carefully in patients with known or suspected GI tract lesions ³.

• Methylnaltrexone dosing for chronic noncancer pain: 450 mg orally or 12 mg subcutaneously once daily ³.
• Naloxegol, another peripheral antagonist, is 25 mg daily; maintenance laxatives are stopped before starting it and may resume as needed after 3 days ⁶.
• Naloxegol is contraindicated with strong CYP3A4 inhibitors such as clarithromycin and ketoconazole ⁶.
• Reduce methylnaltrexone dose when creatinine clearance is below 60 mL/min ³.
• Avoid combining methylnaltrexone with other opioid antagonists, which raises withdrawal risk ³.
• Most patients complete detoxification for narcotic bowel syndrome, but about half resume opioids within 3 months ⁴.
• Psychiatric comorbidity, catastrophizing and substance use are common in narcotic bowel syndrome and impede durable response ⁴.
• Reported cases improved with supervised opioid withdrawal, often via a methadone taper, plus neuromodulators such as low-dose amitriptyline ⁵.

• Starting a stool softener alone as opioid bowel prophylaxis ².
• Assuming naloxegol requires changing the opioid regimen; the label says it does not ⁶.
• Using methylnaltrexone for prevention or with suspected obstruction ³.
• Escalating opioids for pain that worsens with each dose increase ⁴.